Back to Oncology
OncologyvCTCAE v5.0Evidence-Based

Immune-Related Adverse Events for Renal Toxicities - Nephritis

Grades severity of nephritis secondary to immune checkpoint inhibitor (ICPi) therapy based on Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 criteria. This standardized grading system evaluates serum creatinine levels, renal function changes, and clinical symptoms to determine the severity of immune-mediated nephritis and guide clinical management decisions including ICPi therapy continuation, corticosteroid treatment, nephrology consultation needs, and monitoring for life-threatening renal complications. ICPi-induced nephritis has an incidence of 1-2% in single-agent therapy and 4.5% in combination therapy, with median onset at 14 weeks (range 6.5-21 weeks). The calculator provides evidence-based management recommendations essential for oncologists, nephrologists, and multidisciplinary teams managing patients on immunotherapy.

Clinical Input Parameters

mg/dL
Range: 0.3 — 15 mg/dL
mg/dL
Range: 0.3 — 30 mg/dL
Clinical Assessment
Awaiting Parameters
grade
—grade
Ready to Calculate

Awaiting Clinical Input

Enter the clinical input parameters on the left and click Run Clinical Assessment to evaluate this medical calculator with deterministic clinical scoring.

Open in Web App
Clinical decision support tool for licensed medical practitioners. Confirm independently before prescribing or clinical action.

When & Why to Use

The Immune-Related Adverse Events for Renal Toxicities - Nephritis is utilized in clinical practice for risk stratification, diagnostic probability estimation, and treatment decision-making within oncology.

Use this tool during initial patient intake, emergency department workup, or bedside assessment when objective clinical scoring is required to guide management or admission decisions.

Clinical Formula & Scoring Logic

CTCAE grading based on serum creatinine fold increase over baseline: Grade 1: 1.5-2× baseline; Grade 2: 2-3× baseline; Grade 3: >3-6× baseline; Grade 4: >6× baseline OR dialysis required

Clinical Pearls & Practice Notes

  • ICPi-induced nephritis incidence: 1-2% single-agent, 4.5% combination therapy
  • Median time to onset: 14 weeks (range 6.5-21 weeks after treatment initiation)
  • Most common pathology: acute tubulointerstitial nephritis (AIN)
  • Less common manifestations: glomerular disease, thrombotic microangiopathy
  • Baseline creatinine essential for accurate grading - obtain before ICPi initiation
  • Monitor creatinine before each treatment cycle and as clinically indicated
  • Rule out alternative causes: dehydration, medications, contrast nephropathy, obstruction
  • Kidney biopsy recommended for Grade 3-4 or when diagnosis unclear
  • Grade 2+ requires holding ICPi and nephrology consultation
  • Permanent ICPi discontinuation recommended for Grade 3-4 nephritis
  • Corticosteroids are first-line treatment for Grade 2-4 nephritis
  • Second-line agents for steroid-refractory cases: mycophenolate mofetil, calcineurin inhibitors
  • Monitor for electrolyte abnormalities and acid-base disorders
  • Consider empiric treatment without biopsy if typical presentation and exclusion of other causes

Evidence & Literature Citations

  1. Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018 Jun 10;36(17):1714-1768. doi: 10.1200/JCO.2017.77.6385.
  2. Thompson JA, Schneider BJ, Brahmer J, Andrews S, Armand P, Bhatia S, et al. NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020. J Natl Compr Canc Netw. 2020 Mar 1;18(3):230-241. doi: 10.6004/jnccn.2020.0012.
  3. Cortazar FB, Marrone KA, Troxel AB, Ralto KM, Hoenig MP, Brahmer JR, et al. Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors. Kidney Int. 2016 Sep;90(3):638-47. doi: 10.1016/j.kint.2016.04.008.
  4. Shirali AC, Perazella MA, Gettinger S. Association of Acute Interstitial Nephritis With Programmed Cell Death 1 Inhibitor Therapy in Lung Cancer Patients. Am J Kidney Dis. 2016 Aug;68(2):287-91. doi: 10.1053/j.ajkd.2016.02.057.

Score Interpretation Ranges

Grade 11 – 1 pts

Mild - Creatinine 1.5-2× baseline

Grade 22 – 2 pts

Moderate - Creatinine 2-3× baseline

Grade 33 – 3 pts

Severe - Creatinine >3-6× baseline

Grade 44 – 4 pts

Life-threatening - Creatinine >6× baseline OR dialysis required

Need Clinical Suite Access?

Run this calculator with patient history, laboratory integration, and drug interaction safety checks on the DexaMed clinician app.

Open in Web App

Clinical Decision Support (CDS) Notice & Legal Disclaimer

This medical calculator and its scoring interpretation are provided strictly for licensed healthcare professionals and medical trainees as an educational and clinical decision support instrument. It does not replace independent clinical judgment, comprehensive patient history, physical examination, or attending physician oversight. Not FDA-cleared as an autonomous diagnostic medical device. Read the full DexaMed Medical Disclaimer.